Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: The population-based Rotterdam Study

British Journal of Clinical Pharmacology

Volumn 80, Issue 4, 2015, Pages 698-705

  Maljuric, Nevena M ^a   Noordam, Raymond ^a   Aarts, Nikkie ^a   Niemeijer, Maartje N ^a   Van Den Berg, Marten E ^a   Hofman, Albert ^a   Kors, Jan A ^a   Stricker, Bruno H ^a,b   Visser, Loes E ^a,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Health Care Inspectorate   (Netherlands)

^c Apotheek Haagse Ziekenhuizen   (Netherlands)

Author keywords

electrocardiography; population surveillance; serotonin re uptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; ELECTROCARDIOGRAPH; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; QTC INTERVAL; TREATMENT RESPONSE; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; DRUG EFFECTS; DRUG UTILIZATION; FACTUAL DATABASE; HEALTH SURVEY; LONG QT SYNDROME; NETHERLANDS;

AGED; CITALOPRAM; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION; ELECTROCARDIOGRAPHY; FEMALE; HEALTH SURVEYS; HEART RATE; HUMANS; LONG QT SYNDROME; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; SEROTONIN UPTAKE INHIBITORS;

EID: 84942552865     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12681     Document Type: Article

References (44)

1. Myerburg RJ, Kessler KM, Castellanos A,. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993; 119: 1187-97.
2. Myerburg RJ, Interian A, Jr., Mitrani RM, Kessler KM, Castellanos A,. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol 1997; 80: 10F-19F.
3. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ,. Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003; 24: 1204-9.
4. Zipes DP, Wellens HJ,. Sudden cardiac death. Circulation 1998; 98: 2334-51.
5. Roden DM,. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-22.
6. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J, Deckers JW, Kingma JH, Sturkenboom MC, Stricker BH, Witteman JC,. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006; 47: 362-7.
7. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, Davignon A,. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992; 8: 690-5.
8. Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, Kingma JH, Stricker BH,. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005; 26: 2007-12.
9. van Noord C, Rodenburg EM, Stricker BH,. Invited commentary: sex-steroid hormones and QT-interval duration. Am J Epidemiol 2011; 174: 412-5.
10. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K, Bis JC, Marciante K, Rivadeneira F, Noseworthy PA, Sotoodehnia N, Smith NL, Rotter JI, Kors JA, Witteman JC, Hofman A, Heckbert SR, O'Donnell CJ, Uitterlinden AG, Psaty BM, Lumley T, Larson MG, Stricker BH,. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet 2009; 41: 399-406.
11. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J,. The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 2002; 300: 543-8.
12. + channels by the antidepressant drug paroxetine. Biol Pharm Bull 2014; 37: 1495-504.
13. Lee HA, Kim KS, Hyun SA, Park SG, Kim SJ,. Wide spectrum of inhibitory effects of sertraline on cardiac ion channels. The Korean J Physiol Pharmacol: Official Journal of The Korean Physiol Soc, Korean Soc Pharmacol 2012; 16: 327-32.
14. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC,. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002; 512: 59-66.
15. De Ponti F, Poluzzi E, Montanaro N,. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001; 57: 185-209.
16. Woosley RL,. Drugs that prolong the QTc interval and/or induce torsade de pointes. Available at http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/ (last accessed 22 August 2014).
17. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH,. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346: f288.
18. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC,. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry 2014; 75: e441-9.
19. American Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available at http://www.fda.gov/drugs/drugsafety/ucm269086.htm (last accessed 9 September 2014).
20. American Food, and, Drug Administration,. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available at: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (last accessed 9 September 2014).
21. van Noord C, Straus SM, Sturkenboom MC, Hofman A, Aarnoudse AJ, Bagnardi V, Kors JA, Newton-Cheh C, Witteman JC, Stricker BH,. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009; 29: 9-15.
22. Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A, Ikram MA, Klaver CC, Nijsten TE, Peeters RP, Stricker BH, Tiemeier HW, Uitterlinden AG, Vernooij MW,. The Rotterdam Study: 2014 objectives and design update. Eur J Epidemiol 2013; 28: 889-926.
23. Aarts N, Noordam R, Hofman A, Tiemeier H, Stricker BH, Visser LE,. Utilization patterns of antidepressants between 1991 and 2011 in a population-based cohort of middle-aged and elderly. Eur Psychiatry 2014; 29: 365-70.
24. Sagie A, Larson MG, Goldberg RJ, Bengtson JR, Levy D,. An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). Am J Cardiol 1992; 70: 797-801.
25. Sarma JS, Sarma RJ, Bilitch M, Katz D, Song SL,. An exponential formula for heart rate dependence of QT interval during exercise and cardiac pacing in humans: reevaluation of Bazett's formula. Am J Cardiol 1984; 54: 103-8.
26. Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, van Herpen G, Wagner GS, Wellens H,. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009; 53: 982-91.
27. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA,. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-22.
28. Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK,. Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol 2006; 46: 598-612.
29. de Bruyne MC, Kors JA, Hoes AW, Kruijssen DA, Deckers JW, Grosfeld M, van Herpen G, Grobbee DE, van Bemmel JH,. Diagnostic interpretation of electrocardiograms in population-based research: computer program research physicians, or cardiologists? J Clin Epidemiol 1997; 50: 947-52.
30. van Bemmel JH, Kors JA, van Herpen G,. Methodology of the modular ECG analysis system MEANS. Methods Inf Med 1990; 29: 346-53.
31. Willems JL, Abreu-Lima C, Arnaud P, van Bemmel JH, Brohet C, Degani R, Denis B, Gehring J, Graham I, van Herpen G, et al., The diagnostic performance of computer programs for the interpretation of electrocardiograms. N Engl J Med 1991; 325: 1767-73.
32. Willems JL, Arnaud P, van Bemmel JH, Bourdillon PJ, Degani R, Denis B, Graham I, Harms FM, Macfarlane PW, Mazzocca G, Meyer J, Zywiets C, for the Common Standard for Qunatitative Electrocardiography (CSE) Working Party. A reference data base for multilead electrocardiographic computer measurement programs. J Am Coll Cardiol 1987; 10: 1313-21.
33. Kors JA, van Herpen G,. Methodology of QT-interval measurement in the modular ECG analysis system (MEANS). Ann Noninvasive Electrocardiol 2009; 14 Suppl 1: S48-53.
34. Nanchen D, Leening MJ, Locatelli I, Cornuz J, Kors JA, Heeringa J, Deckers JW, Hofman A, Franco OH, Stricker BH, Witteman JC, Dehghan A,. Resting heart rate and the risk of heart failure in healthy adults: the Rotterdam Study. Circ Heart Fail 2013; 6: 403-10.
35. Fridericia L., Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand 1920; 53: 469-86.
36. American Food and Drug Administration. Guidance for Industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf (last accessed 27 June 2015).
37. World Health Organization. International society of hypertension guidelines for the management of hypertension. Guidelines subcommittee. J Hypertens 1999; 17: 151-83.
38. Leening MJ, Kavousi M, Heeringa J, van Rooij FJ, Verkroost-van Heemst J, Deckers JW, Mattace-Raso FU, Ziere G, Hofman A, Stricker BH, Witteman JC,. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol 2012; 27: 173-85.
39. Wolfinger R., Covariance structure selection in general mixed models. Commun Stat-Simul C 1993; 22: 1079-106.
40. American Food and Drug Administration. Guidance for Industry: E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf (last accessed 27 June 2015).
41. van Haelst IM, van Klei WA, Doodeman HJ, Warnier MJ, De Bruin ML, Kalkman CJ, Egberts TC,. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study. J Clin Psychiatry 2014; 75: 15-21.
42. Vieweg WV, Hasnain M, Howland RH, Hettema JM, Kogut C, Wood MA, Pandurangi AK,. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012; 125: 859-68.
43. Zivin K, Pfeiffer PN, Bohnert AS, Ganoczy D, Blow FC, Nallamothu BK, Kales HC,. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatr 2013; 170: 642-50.
44. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Available at http://www.whocc.no/atcddd/ (last accessed 27 June 2015).